LYNBROOK, N.Y., May 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical companydeveloping first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at SEVEN, Noble Financial Capital Markets' Seventh Annual Equity Conference on Tuesday,
A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://noble.mediasite.com/mediasite/Viewer/?peid=546a50205ba1497a9a06f4122a1b3f071d.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in Europe and has announced European regulatory approval and the first commercial sale in the United Kingdom. Asahi Kasei Pharma Corporation is responsible for marketing XIAFLEX® in Japan. More information about BioSpecifics Technologies Corp. may be found on its website at www.biospecifics.com.
SOURCE BioSpecifics Technologies Corp.
Subscribe to our Free Newsletters!
Malaria is a dangerous disease with lethal consequences that requires protective measures for ...
Merkel cell carcinoma is a rare and a highly aggressive primary skin cancer that grows rapidly and ...
Vitrectomy is a surgical procedure performed to remove a part or whole of the vitreous humor ...View All